Tissue Regenix Group plc
DermaPure® added to the Federal Supply Schedule
Leeds, 02 February 2017 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company today announces DermaPure® a decellularized dermal allograft, utilising Tissue Regenix's patented dCELL® Technology, has been included on the United States Department of Veteran Affairs (VA) Federal Supply Schedule (FSS) via their distribution agreement with ERA Health LLC dba Veteran's Health Medical Supply (VHMS).
The FSS services the largest integrated healthcare system in the US, covering almost 9 million lives, many being military veterans, and includes 152 hospitals and 800 community based outpatient clinics1. Wound care is particularly important within this patient sector, with it being estimated that 1 in 4 military veterans suffers from diabetes, much higher than the US average where 9% of the total population are diabetes sufferers.
The inclusion on the FSS further strengthens the commercial position of DermaPure® within both the inpatient and outpatient settings and offers this customer segment an efficient and effective clinical and economic solution. As announced on the 06 December 2016, DermaPure® was awarded a GPO new technology award after a thorough four step review process determined that the technology offers unique attributes in comparison to the other available treatment options.
For more Information:
Tissue Regenix Group plc Caitlin Pearson Corporate Communications Officer |
Tel: 0330 430 3073 |
Jefferies International Ltd Simon Hardy / Harry Nicholas |
Tel: 020 7029 8000 |
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.
In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.
